Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 5NET 2

Conditions

Neuroendocrine Tumors 6Gastro-enteropancreatic neuroendocrine tumor 3Carcinoid Tumor 2Prostatic Neoplasms 1Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Follicular 1Liver Neoplasms 1Hypoglycemia 1Dumping Syndrome 1Carcinoma 1Adenoma, Islet Cell 1Acromegaly 1

Interventions

Everolimus 8lanreotide 3gallium Ga 68 dotatate 3Octreotide 3Nivolumab 3pasireotide 2lutetium Lu 177 dotatate 2cabozantinib 2Temozolomide 2Sunitinib 2Ga(III)-DOTATOC 2Erlotinib Hydrochloride 2Capecitabine 2zimberelimab 1veliparib 1telotristat ethyl 1recombinant interferon alpha 2b-like protein 1pertuzumab 1pembrolizumab 1olaparib 1nintedanib 1ibrutinib 1ganitumab 1fosbretabulin 1epothilone B 1cixutumumab 1arginyllysine 1TKM-080301 1Sorafenib 1Serotonin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoid Tumor × pasireotide × NET × Clear all
NCT01253161 2023-03-06

Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
29 enrolled 11 charts
EndocrineNET

Carcinoid Tumor, Carcinoma, Neoplasm Metastasis, Neuroendocrine Tumors

NCT00804336 2016-10-19

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 1 Completed
22 enrolled
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡